Browse studies

Find your next paid study

1,252 recruiting studies matching your filters

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worl…

Non Small Cell Lung Carcinoma

An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1

This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the …

Non-Small Cell Lung CancerUrothelial Cancer

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07140315

Phase 2

A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizuma…

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more

Estimated

~$10 – $5,625

Phase 2

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatm…

Ovarian CancerFallopian Tube Cancer

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT05287451

Phase 1

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a s…

Small Cell Lung CancerLarge Cell Neuroendocrine Lung CarcinomaExtrapulmonary Neuroendocrine Carcinoma of Small Cell Histology+1 more

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07707895

Phase 2

Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the…

Pancreas AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT05825066

Phase 2

A Phase 2 Trial of Single-Agent Pirtobrutinib for Elderly Patients With CLL

This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inh…

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Estimated

~$10 – $7,500

Jennifer WoyachNCT07685717

Phase 1

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents …

NSCLC AdenocarcinomaGastroesophageal Cancer (GC)Gastric Adenocarcinoma+10 more

Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07277413

Phase 1

A Phase 1 Study to Investigate PF-08046033 in Participants With Advanced Solid Tumors

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine i…

Non-Small-Cell LungEsophageal CancerCutaneous Melanoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Estimated

~$10 – $8,750

TORL Biotherapeutics, LLCNCT07439653

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lympho…

Waldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaMonoclonal B-Cell Lymphocytosis+2 more

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00923507